Spinning a solution in healthcare from a basic technology requires phased research from basic to translational, pre-clinical and clinical studies, for which Japan has a wholesome ecosystem; GN Corp track record, interviewed for a feature story, sponsored by Government of Japan, published in Bloomberg.
“neu REFIX ” potentials in Duchenne Muscular Dystrophy will be presented at MENA Rare Diseases Conference in UAE
19/4/2024
“neu REFIX ” potentials in Duchenne Muscular Dystrophy will be presented at Congress held in UAE
